Goodman Cancer Research Centre, McGill University, Montréal, QC, H3G 1Y6, Canada.
Trends Cancer. 2020 Apr;6(4):337-347. doi: 10.1016/j.trecan.2020.01.015. Epub 2020 Feb 18.
Androgen and its receptor (AR) are major drivers of prostate cancer (PCa), a leading cause of mortality in aging men. Thus, understanding the numerous mechanisms by which AR can promote the growth and proliferation of PCa cells and enable their escape from hormone-dependent therapies, eventually leading to metastasis and death of the patient, is essential to discover alternative therapeutic approaches. Recently, two structurally related members of the phosphatidylinositol 3-kinase-like protein kinase (PIKK) family, DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), were shown to have a direct role in modulating AR activity on chromatin of PCa cells. In this review, the common features of DNA-PK and mTOR and the similarities in their noncanonical roles as transcription coregulators of the AR are highlighted. An outlook on how these findings could be translated into new approaches to manage and treat PCa is provided.
雄激素及其受体(AR)是前列腺癌(PCa)的主要驱动因素,是导致老年男性死亡的主要原因。因此,了解 AR 促进 PCa 细胞生长和增殖并使其逃避激素依赖性治疗的众多机制,最终导致转移和患者死亡,对于发现替代治疗方法至关重要。最近,磷酸肌醇 3-激酶样蛋白激酶(PIKK)家族的两个结构相关成员,即 DNA 依赖性蛋白激酶(DNA-PK)和雷帕霉素的哺乳动物靶标(mTOR),被证明在调节 PCa 细胞染色质上的 AR 活性方面具有直接作用。在这篇综述中,突出了 DNA-PK 和 mTOR 的共同特征,以及它们作为 AR 的转录共调节剂的非典型作用的相似性。提供了如何将这些发现转化为管理和治疗 PCa 的新方法的展望。